Bhupinder Singh

picture of Bhupinder  Singh

Clinical Professor, Medicine
School of Medicine

M.D.

Email: bhupinds@uci.edu

University of California, Irvine
975 Island Drive
Suite 201
Redwood City, CA 94065
Research Interests
CKD, AKI prevention, Nutritional Management of Kidney Diseases, Cardiovascular Disease in CKD, Fluid and Electrolyte Disorders
URLs
Research Abstract
Dr. Singh has been involved in more than 50 clinical trials as a Principal Investigator. He oversaw the development and approval of Sodium Zirconium Cyclosilicate for hyperkalemia; and has also been involved in the development and launch of urea for hyponatremia, enteric coated sodium bicarbonate for metabolic acidosis and keto-analogues of amino acids for nutritional management of CKD.
Publications
1: Roger SD, Spinowitz BS, Lerma EV, Singh B, Packham DK, Al-Shurbaji A,
Kosiborod M. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment
of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE. Am J Nephrol.
2019 Oct 28:1-8. doi: 10.1159/000504078. [Epub ahead of print] PubMed PMID:
31658466.


2: Johnson AC, Gooley T, Guillem A, Keyser J, Rasmussen H, Singh B, Zager RA.
Parenteral Iron Sucrose-Induced Renal Preconditioning: Differential Ferritin
Heavy and Light Chain Expression in Plasma, Urine and Internal Organs. Am J
Physiol Renal Physiol. 2019 Oct 14. doi: 10.1152/ajprenal.00307.2019. [Epub ahead
of print] PubMed PMID: 31608670.


3: Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von
Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M,
Packham DK; ZS-005 Study Investigators. Sodium Zirconium Cyclosilicate among
Individuals with Hyperkalemia: A 12-Month Phase 3 Study. Clin J Am Soc Nephrol.
2019 Jun 7;14(6):798-809. doi: 10.2215/CJN.12651018. Epub 2019 May 20. PubMed
PMID: 31110051; PubMed Central PMCID: PMC6556727.


4: Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman
WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy
ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM,
Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M,
Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F.
Cardiovascular outcome trials in patients with chronic kidney disease: challenges
associated with selection of patients and endpoints. Eur Heart J. 2019 Mar
14;40(11):880-886. doi: 10.1093/eurheartj/ehx209. PubMed PMID: 28431138; PubMed
Central PMCID: PMC6657268.


5: Vijayaraghavan K, McCullough PA, Singh B, Gupta M, Enas E, Mohan V, Misra A,
Deedwania P, Brinton EA; for the Consensus Panel Steering Committee.
Cardiometabolic-Renal Disease in South Asians: Consensus Recommendations from the
Cardio Renal Society of America. Cardiorenal Med. 2019;9(4):240-251. doi:
10.1159/000499341. Epub 2019 May 10. PubMed PMID: 31079117.


6: Fishbane S, Singh B, Kumbhat S, Wisemandle WA, Martin NE. Intravenous Epoetin
Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney
Disease. Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1204-1214. doi:
10.2215/CJN.11631017. Epub 2018 Jun 19. PubMed PMID: 29921734; PubMed Central
PMCID: PMC6086700.


7: Friedman PA, Scott CG, Bailey K, Baumann NA, Albert D, Attia ZI, Ladewig DJ,
Yasin O, Dillon JJ, Singh B. Errors of Classification With Potassium Blood
Testing: The Variability and Repeatability of Critical Clinical Tests. Mayo Clin
Proc. 2018 May;93(5):566-572. doi: 10.1016/j.mayocp.2018.03.013. PubMed PMID:
29728199.


8: Lau WL, Khazaeli M, Savoj J, Manekia K, Bangash M, Thakurta RG, Dang A, Vaziri
ND, Singh B. Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac
hypertrophy in 5/6 nephrectomized rats. Pharmacol Res Perspect. 2018 Feb
19;6(2):e00385. doi: 10.1002/prp2.385. eCollection 2018 Apr. PubMed PMID:
29468071; PubMed Central PMCID: PMC5817151.


9: Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB. Serum Potassium Levels and
Mortality in Hemodialysis Patients: A Retrospective Cohort Study. Am J Nephrol.
2016;44(3):179-86. doi: 10.1159/000448341. Epub 2016 Sep 3. PubMed PMID:
27592170.


10: Anker SD, Kosiborod M, Zannad F, Piña IL, McCullough PA, Filippatos G, van
der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P.
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in
heart failure patients: results from a phase 3 randomized, double-blind,
placebo-controlled trial. Eur J Heart Fail. 2015 Oct;17(10):1050-6. doi:
10.1002/ejhf.300. Epub 2015 Jun 16. PubMed PMID: 26011677; PubMed Central PMCID:
PMC5033065.


11: Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A phase 2 study on the
treatment of hyperkalemia in patients with chronic kidney disease suggests that
the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015
Aug;88(2):404-11. doi: 10.1038/ki.2014.382. Epub 2015 Feb 4. PubMed PMID:
25651363; PubMed Central PMCID: PMC4526769.


12: Packham DK, Rasmussen HS, Singh B. New agents for hyperkalemia. N Engl J Med.
2015 Apr 16;372(16):1571-2. doi: 10.1056/NEJMc1501933. PubMed PMID: 25884064.


13: Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi
W, Pergola P, Singh B. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J
Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21.
PubMed PMID: 25415807.


14: Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger
SD, Yang A, Lerma E, Singh B. Effect of sodium zirconium cyclosilicate on
potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE
randomized clinical trial. JAMA. 2014 Dec 3;312(21):2223-33. doi:
10.1001/jama.2014.15688. Erratum in: JAMA. 2015 Feb 3;313(5):526. Dosage error in
text. PubMed PMID: 25402495.


15: Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D,
Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross
DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT. Ferric carboxymaltose in
patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA
trial. Nephrol Dial Transplant. 2014 Apr;29(4):833-42. doi: 10.1093/ndt/gft251.
Epub 2013 Aug 20. PubMed PMID: 23963731.


16: Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ,
Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI,
Rundback JH, Massaro JM, D'Agostino RB Sr, Dworkin LD; CORAL Investigators.
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J
Med. 2014 Jan 2;370(1):13-22. doi: 10.1056/NEJMoa1310753. Epub 2013 Nov 18.
PubMed PMID: 24245566; PubMed Central PMCID: PMC4815927.


17: de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H,
Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ,
Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D,
Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and
stage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492-503. doi:
10.1056/NEJMoa1306033. Epub 2013 Nov 9. PubMed PMID: 24206459; PubMed Central
PMCID: PMC4496027.


18: Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P,
Smits G, Comelli MC. Effect of salivary phosphate-binding chewing gum on serum
phosphate in chronic kidney disease. Nephron Clin Pract. 2013;123(1-2):93-101.
doi: 10.1159/000351850. Epub 2013 Jun 22. PubMed PMID: 23797006.


19: Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y,
Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D,
Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani
R. Vitamin D reduces left atrial volume in patients with left ventricular
hypertrophy and chronic kidney disease. Am Heart J. 2012 Dec;164(6):902-9.e2.
doi: 10.1016/j.ahj.2012.09.018. Epub 2012 Oct 29. PubMed PMID: 23194491.


20: Narsipur SS, Srinivasan B, Singh B. Effect of simvastatin use on autonomic
function in patients with end stage renal disease. Cardiovasc Hematol Disord Drug
Targets. 2011 Mar 1;11(1):53-7. PubMed PMID: 21446902.


21: Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C,
Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye
J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD. Vitamin D
receptor activation and left ventricular hypertrophy in advanced kidney disease.
Am J Nephrol. 2011;33(2):139-49. doi: 10.1159/000323551. Epub 2011 Jan 18. PubMed
PMID: 21242674.


22: Wilasrusmee C, Da Silva M, Singh B, Siddiqui J, Bruch D, Kittur S,
Wilasrusmee S, Kittur DS. Morphological and biochemical effects of
immunosuppressive drugs in a capillary tube assay for endothelial dysfunction.
Clin Transplant. 2003;17 Suppl 9:6-12. PubMed PMID: 12795661.


23: Wilasrusmee C, Da Silva M, Singh B, Kittur S, Siddiqui J, Bruch D,
Wilasrusmee S, Kittur DS. A new in vitro model to study endothelial injury. J
Surg Res. 2002 May 15;104(2):131-6. PubMed PMID: 12020132.
Professional Society
Cardio Renal Society of America
Other Experience
Vice President, Clinical Development
Allakos 2017

Executive Medical Director of Research
ZS Pharma (acquired by AstraZeneca) 2014—2017

Co-founder, Executive Board Member, VP of Clinical Affairs, Medical Director of Research (various positions between 2003-2013)
Southwest Kidney Institute 2003—2013

Co-founder, Executive Board Member, Immediate PastPresident
Cardio Renal Society of America 2011

Co-Founder
Nephcentric 2014

Executive Board Member
Renibus 2015

Medical Director, Dialysis (different units between 2004-2013)
DSI, Davita 2004—2013

Principal Investigator, Path to Wellness program
National Kidney Foundation of Arizona

Board Member
Nephronet 2014—2017

Board Member
Transplant First Academy

Nephrologist
Desert Kidney Associates 2002—2003

Chief Medical Officer
Apex Research of Riverside 2014—2014

Graduate Programs
Internal Medicine

Nephrology (IM)

Last updated
11/11/2019